Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study.

Paul GlueNatalie J MedlicottShona NeehoffPeter SurmanFred LamNoelyn HungCheung-Tak Hung

Published in: Therapeutic advances in psychopharmacology (2020)

Ketamine's safety/tolerability may be improved with an extended release oral formulation. Onset of mood improvement is slightly delayed compared with parenteral dosing. These data support the further development of extended release ketamine tablets for treatment of resistant depression and anxiety disorders.

Keyphrases

open label
pain management
clinical trial
sleep quality
bipolar disorder
drug delivery
electronic health record
phase ii
phase ii study
phase iii
physical activity
double blind